Wasdell Group granted HPRA licence at new EU headquarters24 Jan 2019
The new Irish facility will allow the company to continue to act as a gateway to Europe for its British and North American customers.
The Wasdell Group has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.
Following a successful HPRA inspection in December 2018, the company - an outsourcing partner for companies in the pharmaceutical and clinical trials industries - is now certified to conduct Qualified Person (QP) batch certification and release of pharmaceutical products to Europe ahead of the facility commencing operations in Spring 2019.
Colin Newbould, Director of Regulatory Affairs and QP services at The Wasdell Group said: “Being accredited with this licence ahead of schedule is testament to our team.
“While this expansion will allow us to cater for increased customer demand, the Dundalk facility is also an integral part of our proactive contingency plan to protect our customers critical supply chains ahead of the UK’s exit from the European Union (EU).
“Receiving the HPRA licence is an important milestone, bringing us closer to finalising what has been a huge project for us. And, with the 29th March Brexit deadline just around the corner, it means our customers can be confident that we can manage any risk associated no matter the outcome.”
The €30-million investment into the Ireland facility was made in 2018 and forms part of the company’s ongoing plans to expand its offering outside of the UK.
The Dundalk facility will offer a full range of contract services including quality control (QC) import testing and batch release for pharmaceutical products, as well as a variety of current and novel packaging technologies. It will also house the company’s largest storage and distribution facilities to date.
Vincent Dunne, CEO of The Wasdell Group said: “With almost 75% of our turnover being a result of export business and a growing customer base in both the Irish and US markets, Dundalk was a logical choice for our EU headquarters.
“The new facility will allow us to continue to act as a gateway to Europe for our British and North American customers.”
The Irish facility comes as the latest phase in the company’s strategic plan to bolster capabilities and capacity, following the recent £500K investment into its new microbiological and analytical laboratory at its Newcastle, UK site.
Leaf Expression Systems launches first line of Hypertrans research products
13 Jun 2019
Plant-expression deal for difficult to produce proteins, vaccines, metabolites and natural proteins.Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.Read more
Combining IT and OT software to solve manufacturing’s most frequent challenges
11 Jun 2019
PTC and Rockwell Automation combine technologies to accelerate customers’ digital transformation initiatives.Read more
Sphere Fluidics secures funding to support its single cell analysis system
11 Jun 2019
Funding will also be used to further expand operations in the UK and US.Read more
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma
6 Jun 2019
Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.Read more
Cambrex completes new process and analytical development facility at Sweden manufacturing site
5 Jun 2019
The process technology laboratories will include new capabilities in the scaling up of potent molecules requiring containment.Read more
Sterling pilot plant facility expansion up and running
4 Jun 2019
Additional three new reactor trains will help the CDMO to meet growing market demand for smaller API batch sizes.Read more
Lilly gets its hands on non-opioid pain asset
4 Jun 2019
Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.Read more
Updated clinical trial simulation software saves time and money
3 Jun 2019
One customer saves $25m and 3 years' development time in their clinical development strategy.Read more
Ampersand Capital Partners to acquire Vibalogics
3 Jun 2019
Vibalogics will expand capabilities to meet rapidly growing demand for development and manufacturing of complex viral products.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation